Appendix D. Evidence Tables

**Table D-1. Characteristics of included randomized trials**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Akuchekian et al., 20041Iran | Randomized: 67G1: 34G2: 33Analyzed:67G1: 34G2: 33 | Iranian Veterans Administration medical center 12 wks | CAPS Baseline & Posttreatment | NR |
| Asukai et al., 20102Japan | Randomized: 24G1: 12G2: 12Post-treatment Analyzed: 24G1: 12G2:12 | Referred by psychiatric clinics or victim-support services; web recruitment - Outpatient8 to 15 weekly sessionsa  | CAPS Baseline, Posttreatment, 3 mths, 6mths, 12 mths  | Government |
| Bartzokis et al., 20053United States | Randomized:65G1: 33G2: 32Analyzed: 48G1: 22G2: 26 | VA med center16 wks | CAPSBaseline & Posttreatment (4 wks residential phase & 16 wks outpatient phase) | Foundation/non-profit & Government |
| Basoglu et al., 20074Turkey | Randomized: 31G1: 16G2: 15Analyzed: Week 4: 30G1: 15G2: 15Analyzed: Week 8: 31G1: 16G2: 15 | Outreach Mental Health Care Delivery Program Single sessiona | CAPS Baseline, 4 wks, 8 wks, 12 wks, 24 wks, 1yr | Foundation/non-profit |
| Becker et al., 20075United States | Randomized:30G1: UnclearG2: UnclearAnalyzed: 28G1: 18G2: 10 | VA med center8 wks | CAPS Baseline & Posttreatment | Pharmaceutical company & Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Blanchard et al., 20036United States | Randomized: 98G1: 37G2: 36G3: 25Analyzed: 98G1: 37G2: 36G3: 25 | Outpatient special MH8 to12 wks | CAPS Baseline, Posttreatment, 3 mths | Government |
| Boden et al., 20127United States | Randomized: 117G1: 59G2: 58Analyzed: 98G1: 49G2: 49 | VA med center | Addiction Severity Index (ASI)Baseline, Posttreatment, 6 mths | Government |
| Brady et al., 20008United States | Randomized: 187G1: 94G2: 93Analyzed: 183G1: 93G2: 90 | Outpatient Psychiatric clinics in academic medical centers and clinical centers12 wks | CAPS-2 & IES Baseline & Posttreatment or at the discontinuation | Pharmaceutical company |
| Brady et al., 20059United States | Randomized: 94G1: 49G2: 45Analyzed: 94G1: 49G2: 45 | Community and Outpatient Substance Abuse Treatment Programs12 wks | CAPSBaseline & Posttreatment | Government |
| Bryant et al., 200310Australia | Randomized: 58G1: 20G2: 20G3: 18Analyzed: 58G1: 20G2: 20G3: 18 | Outpatient special MH8 wks | CAPS Baseline, Posttreatment, 6 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Bryant et al., 200811Australia | Randomized: 118G1: 31G2: 28G3: 31G4: 28Analyzed: 118G1: 31G2: 28G3: 31G4: 28 | Outpatient special MH8 wks | CAPS Baseline, Posttreatment, 6 mths | Government |
| Butterfield et al., 200112United States | Randomized: 15G1: 10G2: 5Analyzed: 15G1: 10G2: 5 | Military10 wks | CAPS-2Baseline & Posttreatment | Pharmaceutical company |
| Carlson et al., 199813United States | Randomized: 35G1: 10G2: 13G3: 12Analyzed: 34G1:10G2:12G3:12 | VA med center6 wks | CAPSBaseline, posttreatment, 3 mths, 9 mths | Government |
| Chard et al., 200514United States | Randomized: 71G1: 36G2: 35Analyzed: 55G1: 28G2: 27 | Community17 wks | CAPS-SX Baseline, Posttreatment, 3 mths, 1 yr  | Government |
| Cloitre et al., 200215United States | Randomized: 58G1: 31G2: 27Analyzed:46G1: 22G2: 24 | Community12 mths | PTSD Sx improvement Baseline, Posttreatment, 3 mths, 9 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Cloitre et al., 201016United States | Randomized: 104G1: 33G2: 38G3: 33Analyzed:104G1: 33G2: 38G3: 33 | Outpatient special MH16 wks | CAPS & PSS-SRBaseline, Posttreatment, 3 mths, 6 mths | Government |
| Connor et al., 199917Meltzer-Brody et al., 200018United States | Randomized: 54G1: 27G2: 27Analyzed: 53G1: 27G2: 26 | Community12 wks | Duke Global Rating for PTSD Baseline, Posttreatment or at the discontinuation if prior to week 12 | Government |
| Cook et al., 201019United States | Randomized: 124G1: 61G2: 63Analyzed: 101G1: 45G2: 56 | Outpatient special MH6 wks | CAPSBaseline, Posttreatment, 1 month, 3 mths, 6 mths  | Government |
| Cottraux, 200820France | Randomized: 60G1: 31G2: 29Analyzed:60G1:31G2:29 | Outpatient special MH16 wks  | General Criterion of Improvement (i.e., score <35 on the post-traumatic checklist scale)Baseline, Posttreatment, 1yr, 2 yrs  | Government |
| Davidson et al., 200121United States | Randomized: 208G1: 100G2: 108Analyzed: 202G1: 98G2: 104 | Study Centers–Outpatient12 wks | CAPS-2 & IESBaseline & Posttreatment or week of discontinuation if before week 12 | Pharmaceutical company |
| Davidson et al., 200322United States | Randomized: 29 G1: UnclearG2: UnclearAnalyzed:26G1: 17G2: 9 | Outpatient special MH8 wks | SPRINTBaseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Davidson et al., 200623United States | Randomized: 538G1: NRG2: NRG3: NRAnalyzed: 531G1: 179G2: 173G3: 179 | Outpatient PC12 wks | CAPSBaseline & Posttreatment | Pharmaceutical company |
| Davidson et al., 200624Argentina, Chile, Colombia, Denmark, Finland, Mexico, Norway, Portugal, South Africa, Spain, Sweden, and United Kingdom | Randomized: 329G1: 161G2: 168Analyzed: 329G1: 161G2: 168 | Outpatient PC24 wks | CAPS-SX Baseline and posttreatment or at the time of discontinuation if before week 24 | Pharmaceutical company |
| Davidson et al., 200725United States | Randomized: 232G1: 116G2: 116Analyzed: 202G1: 105G2: 97 | Outpatient special MH12 wks | CAPS, DTS & TOP-8 Baseline & Posttreatment | Pharmaceutical company |
| Davis et al., 200826United States | Randomized: 85G1: 44G2: 41Analyzed:G1:41G2:41 | VA med center8 wks | CAPSBaseline & Posttreatment | Government |
| Ehlers et al., 200327United Kingdom | Randomized: 85G1: 28G2: 28G3: 29Analyzed:78G1: 28G2: 25G3: 25 | Outpatient special MHMean: 9 wks; 0-3 booster sessions | CAPS & PDSBaseline, Posttreatment, 3 mths, 6 mths, 9 mths | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Ehlers et al., 200528United Kingdom | Randomized: 28G1: 14G2: 14Analyzed: 28G1: 14G2: 14 | Outpatient PC4 to 12 wks and up to 3 monthly booster sessions | CAPS Baseline, Posttreatment, 6 mths | Foundation/non-profit |
| Fecteau et al., 199929Canada | Randomized: 23G1: 12G2: 11Analyzed: 20G1: 10G2: 10 | Outpatient special MH4 wks | CAPS-2, Baseline, Posttreatment, 3 mths, 6 mths | Foundation/non-profit |
| Foa et al., 199930Zoellner et al., 199931United States | Randomized: 96G1: 25G2: 26G3: 30 G4: 15Analyzed: 79G1: 23G2: 19G3: 22G4: 15 | NR9 wks | PSS-I Baseline, Posttreatment, 3 mths, 6 mths, 12 mths | Government |
| Foa et al., 200532United States | Randomized: 190G1: NR G2: NRG3: NRAnalyzed: 179G1: 79G2: 74G3: 26 | Community and Academic Specialty Clinic12 wks (9-12 sessions, 1 session per week) | PSS-IBaseline, Posttreatment, 3 mths, 6 mths, 12 mths  | Government |
| Forbes et al., 201233Australia | Randomized: 59G1: 30G2: 29Analyzed:59G1: 30G2:29 | Veterans and Veterans Families Counseling Service12 wks | CAPSBaseline, Posttreatment, 3 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Ford et al., 201134United States | Randomized:146G1: 48G2: 53G3: 45Analyzed: 146G1: 48G2: 53G3: 45 | Community12 sessionsa | CAPSBaseline, Posttreatment, 3 mths, 6 mths | Government |
| Friedman et al., 200735United States | Randomized: 169G1: 86G2: 83Analyzed:166G1: 84G2: 82 | VA med center12 wks | CAPS-2 Baseline & Posttreatment | Pharmaceutical company |
| Gamito et al., 201036Portugal | Randomized: 10G1: 5G2: 2G3: 3Analyzed:9G1: 4G2: 2G3: 3 | Military12 Sessionsa | CAPSBaseline & Posttreatment  | Government |
| Gersons et al., 200037Netherlands | Randomized: 42G1: 22G2: 20Analyzed: 42G1: 22G2:20 | Referred by occupational physicians, police department 16 wks  | SI-PTSD & SCL-90Baseline, Posttreatment, 3 mths | Government |
| Hamner et al., 200338United States | Randomized:40G1: 20G2: 20Analyzed: 37G1: 19G2: 18 | Military5 wks | CAPSBaseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Hien et al., 200439United States | Randomized:128G1: UnclearG2: UnclearG3: 32 (non-random)Analyzed: 107G1: 41G2: 34G3: 32 | Community12 wks | CAPS & IESBaseline, Posttreatment, 6 mths, 9 mths follow-up | Government |
| Hien et al., 200940Hien et al., 201241United States | Randomized: 353G1: 176G2: 177Analyzed:289G1: 140G2: 149 | Community6 wks | CAPSBaseline & Posttreatment | Government |
| Hinton et al., 200542United States | Randomized: 40G1: 20G2: 20Analyzed: 40G1: 20G2: 20 | Outpatient special MH12 wks | CAPSBaseline, Posttreatment, 12 wks after the completion of therapy | NR |
| Hinton et al., 200943United States | Randomized: 24G1: 12G2: 12Analyzed:24G1: 12G2: 12 | Community12 wks | CAPSBaseline & Posttreatment | NR, but at least 1 author has pharmaceutical affiliation |
| Hinton et al., 201144United States | Randomized: 24G1: 12G2: 12Analyzed: 24G1: 12G2: 12 | Community14 wks  | PTSD checklistBaseline, Posttreatment, 12 wks | Government |
| Hogberg et al., 200745Sweden | Randomized: 24G1: 13G2: 11Analyzed: 21G1: 12G2: 9 | Employees of the public transportation system - Outpatient2 mths | PTSD dxMean 10 days after treatment (last month of study) | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Hollifield et al., 200746United States | Randomized: 84G1: 29G2: 28G3: 27Analyzed:73G1: 24G2: 25G3: 24 | Outpatient special MH12 wks | PSS-SRBaseline, Posttreatment, 3 mths | Government |
| Johnson et al., 201147United States | Randomized: 70G1: 35G2: 35Analyzed: 70G1: 35G2: 35 | Community8 mths | CAPSBaseline & Posttreatment, 1 week, 3 mths, 6 mths | Government |
| Krakow et al., 200148United States | Randomized: 186G1: 88G2: 80Analyzed: 114G1:54G2:60 | Community5 wks | PSS & CAPSBaseline, Posttreatment, 3 mths, 6 mths | Government |
| Kruse et al., 200949Germany | Randomized: 70G1: 35G2: 35Analyzed:64G1: 34G2: 30 | Yugoslavian Refugees3 month weekly sessions; after that once every 2 wks for a total of 25 hours of therapy | HTQ Baseline, Posttreatment, 12 mths  | Academic |
| Krystal et al., 201150United States | Randomized: 296G1: 147G2: 149Analyzed: 247G1: 123G2: 124 | VA med center24 wks | CAPSBaseline & Posttreatment | Government |
| Kubany et al., 200351United States | Randomized: 37G1: 19G2: 18Analyzed: 32G1:18G2:14 | NR4.5 mths (7 to 10 sessions)) | PTSD remissionBaseline, Posttreatment, 3 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Kubany et al., 200452United States | Randomized:125G1: 63G2: 62Analyzed:125G1: 63G2: 62 | Community4 to 5.5 wks | CAPSBaseline, Posttreatment, 3 mths, 6mths | Government |
| Liedl et al., 201153Germany & Switzerland | Randomized: 36G1: 12G2: 12G3: 12Analyzed:30G1: 10G2: 10G3:10 | Outpatient special MHAverage treatment of 4.8 mths | PDS Baseline & Posttreatment | NR |
| Lindauer et al., 200554The Netherlands | Randomized: 24G1: 12G2: 12Analyzed: 24G1: 12G2: 12 | Outpatient PC16 wks | SI-PTSD Baseline & Posttreatment | Government |
| Litz et al., 200755United States | Randomized: 45G1: 24G2: 21Analyzed:G1:23G2:20 | Military8 wks  | PTSD Symptom Scale - Interview VersionBaseline, Posttreatment, 3 mths, 6 mths | Government |
| Marks et al., 199856Lovell et al., 200157England | Randomized: 87G1: 23G2: 19G3: 24G4: 21Analyzed: 77G1: 20G2: 18G3: 19G4: 20 | Community10 wks | CAPS-2, IES Baseline, Posttreatment, 1 month, 3 mths, 6 mths | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Marshall et al., 200158United States | Randomized: 563G1: 188G2: 187G3: 188Analyzed:551G1: 183G2: 182G3: 186 | NR–Outpatient12 wks | CAPS-2Baseline & Posttreatment | Pharmaceutical company & Government |
| Martenyi et al., 200259Martenyi et al., 200660Belgium, Bosnia, Croatia, Yugoslavia Israel, & South Africa | Randomized: 301G1: 226G2: 75Analyzed: 301G1: 226G2: 75Subgroup Analysis: 144G1: 110G2: 34 | Other - Study Centers (Outpatient, but not clear)12 wks | TOP-8Baseline & Posttreatment | Pharmaceutical company |
| Martenyi et al., 200761United States | Randomized:411G1: 163G2: 160G3: 88Analyzed:298G1:114G2:120G3: 64 | Study Centers -Outpatient12 wks | TOP-8Baseline & Posttreatment | Pharmaceutical company |
| McDonagh et al., 200562United States | Randomized: 74G1: 29G2: 22G3: 23Analyzed: 74G1: 29G2: 22G3: 23 | NR 14 wks | CAPS Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Monnelly et al., 200363United States | Randomized: 16G1: 8G2: 8Analyzed:15G1:7G2:8 | VA med center6 wks | PCL-MBaseline & Posttreatment | Foundation/non-profit & Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Monson et al., 200664United States | Randomized: 60G1: 30G2: 30Analyzed: 60G1: 30G2: 30 | VA med center12 sessions (twice weekly)a | CAPS Baseline, Posttreatment, 1 month  | Government |
| Mueser et al., 200865United States | Randomized: 108G1: 54G2: 54Analyzed: 59G1: 32G2: 27 | Outpatient special MH12 to16 sessionsa | CAPS-Total Baseline, Posttreatment, 3 mths, 6 mths | Government |
| Nacasch et al., 201166Israel | Randomized:30G1: 15G2: 15Analyzed:30G1:15G2:15 | VA med center9 to 15 weeks | PSS-IBaseline, Posttreatment, 12 mths | NR |
| Neuner et al., 200467Uganda & Sudan | Randomized: 43G1: 17G2: 14G3: 12Analyzed: 43G1: 17G2: 14G3: 12 | Sudanese Refugees in a Ugandan refugee settlement3 to 4 wks | Posttraumatic Stress Diagnostic Scale Baseline, Posttreatment, 4 mths, 1 yr | Foundation/non-profit |
| Neuner et al., 200868Uganda | Randomized: 277G1: 111G2: 111G3: 55Analyzed: 277G1: 111G2: 111G3: 55 | Rwandan and Somalian refuges in a Ugandan refugee settlement3 wks | Posttraumatic Stress Diagnostic ScaleBaseline, Posttreatment, 6 mths  | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Neuner et al., 201069Germany | Randomized: 32G1: 16G2: 16Analyzed:32G1: 16G2: 16 | Outpatient special MHSessions were scheduled on a weekly or bi-weekly basis, with a median of 9 treatment sessions. Treatment was terminated at the discretion of the therapist, with a range of 5 to 17 sessionsa | PDS Baseline, Posttreatment, 6 mths | Foundation/non-profit |
| Nijdam et al., 201270The Netherlands | Randomized:140G1: 70G2: 70Analyzed: 140G1:70G2:70 | Outpat special MH17 wks | IES-RBaseline & Posttreatment | Academic |
| Panahi et al., 201171Iran | Randomized:70G1: 35G2: 35Analyzed:G1: 35G2:35 | Outpat special MH10 wks | IES-RBaseline & Posttreatment | Academic |
| Petrakis et al., 201172United States | Randomized:88G1: 22G2: 20G3: 22G4: 24Analyzed: 88G1: 22G2: 20G3: 22G4: 24 | Veterans from outpatient clinics and nonveterans outpatients from the community 12 wks | CAPS Baseline & Posttreatment | Government |
| Raskind et al., 200373United States | Randomized: 10G1: 5G2: 5Analyzed:10G1: 5G2: 5 | VA med center20 wks | CAPS “Recurrent Distressing Dreams Scale”Baseline & Posttreatment | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Raskind et al., 200774United States | Randomized: 40G1: 20G2: 20Analyzed: 34G1: 17G2: 17 | VA med center8 wks | CAPS "Recurrent Distressing Dreams & PSQIBaseline & Posttreatment | Government |
| Reich et al., 200475United States | Randomized: 21G1: 12G2: 9Analyzed: 21G1: 12G2: 9 | Community8 wks | CAPS-1 and CAPS-2 Both at baseline and at 1 wk, 2 wks, 4 wks, 8 wks; CAPS-1 readministered at 8 wks | Pharmaceutical company |
| Resick et al., 200276Resick et al., 200377Resick et al., 201278United States | Randomized: 181G1: NRG2: NR G3: NR Analyzed: 171G1: 62G2: 62 G3: 47Avaliable for LTFU: 126G1: 63G2: 63 | NR6 wks  | CAPSBaseline, posttreatment, 3 mths, 9 mths, 5 to 10 years | Government |
| Rothbaum et al., 199779United States | Randomized: 21G1: UnclearG2: UnclearAnalyzed:18G1: 10G2: 8 | Outpatient special MH4 wks | PSSBaseline & Posttreatment | Academic |
| Rothbaum et al., 200580United States | Randomized: 72G1: 24G2: 26G3: 24Analyzed:60G1: 20G2: 20G3: 20 | Outpatient special MH4.5 wks | CAPSBaseline, posttreatment, 6 mths | Government |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Rothbaum et al., 200681United States | Randomized: 65G1: 34G2: 31Analyzed: 65G1: 34G2: 31 | Outpatient special MH6 wks | SI-PTSDBaseline & Posttreatment | Pharmaceutical company |
| Schneier et al., 201282United States | Randomized: 37G1: 19G2: 18Analyzed:37G1:19G2:18  | Outpatient special MH10 wks | CAPSBaseline & Posttreatment | Government |
| Schnurr et al., 200383United States | Randomized: 360G1: 180G2: 180Analyzed: 325G1: 162G2: 163 | VA med center30 wks active treatment and 5 subsequent monthly booster sessions (12 mths total) | CAPS Baseline, posttreatment, at the end of the booster sessions; 12 mths, 18 mths, 24 mths | Government |
| Schnurr et al., 200784United States | Randomized: 284G1: 141G2: 143Analyzed: 284G1: 141G2: 143 | VA med center10 wks | CAPSBaseline, posttreatment, 3 mths, 6 mths | Government |
| Schnyder et al., 201185Switzerland | Randomized: 30G1: 16G2: 14Analyzed: 30G1: 16G2: 14 | NR16 wks | CAPS Baseline, posttreatment, 6 mths | Foundation/non-profit & Academic |
| Simon et al., 200886United States | Randomized: 25G1: 11G2: 14Analyzed: 23G1: 9G2: 14 | Outpatient PC10 wks | SPRINTBaseline & posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Spence et al., 201187Australia | Randomized: 44G1: 23G2: 21Analyzed:42G1: 23G2:19 | Community8 wks | PCL-CBaseline, posttreatment, 3mths | Academic |
| Stein et al., 200288United States | Randomized:19 G1: 10G2: 9Analyzed:19G1: 10G2: 9 | VA med center8 wks | CAPSBaseline & Posttreatment | Pharmaceutical company |
| Tarrier et al., 199989Tarrier et al., 199990England | Randomized: 72G1: 35G2: 37Analyzed : 62 G1: 29G2: 33 | Referred from primary, secondary, & voluntary health services - Outpatient16 sessions (over 112 days)a | CAPS, Penn Inventory, & IES Baseline, Posttreatment, 6 mths, 12 mths | Foundation/non-profit |
| Taylor et al., 200391Canada | Randomized:60G1: 19G2: 22 G3: 19Analyzed:45G1: 15G2: 15 G3: 15 | Outpatient special MH8 wks | CAPSBaseline, Posttreatment, 1 month, 3 mths | Foundation/non-profit |
| Tucker et al., 200192United States and Canada | Randomized: 323G1: 163G2: 160Analyzed: 307G1: 151G2: 156 | Other–Outpatient12 wks | CAPS-2Baseline & Posttreatment | Pharmaceutical company |
| Tucker et al., 200393Tucker et al., 200494United States | Randomized: 59G1: 25G2: 23G3: 10Analyzed: 58G1: unclearG2: unclearG3: unclear | Outpatient special MH10 wks | CAPSBaseline & Posttreatment | Pharmaceutical company |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Tucker et al., 200795United States | Randomized: 40G1: 20G2: 20Analyzed:38G1: 19G2: 19 | Outpatient special MH12 wks | CAPS Baseline & Posttreatment | Pharmaceutical company |
| van der Kolk et al., 199496United States | Randomized: 64G1: 33G2: 31Analyzed: 47G1: 21G2: 27 | Hospital Trauma Clinic & VA Outpatient Clinic5 wks | CAPS Baseline & Posttreatment | Pharmaceutical company |
| van der Kolk et al., 200797United States | Randomized: 88G1: 29G2: 30G3: 29Analyzed: 88G1: 29G2: 30G3: 29 | Outpatient special MH8 wks | CAPSBaseline, Posttreatment, 6 mths | Government |
| van Emmerik et al., 200898Netherlands | Randomized:125G1: 41G2: 44G3:40Analyzed:125G1:41G2:44G3:40 | Outpatient special MH5 sessions (Overall Mean 119.49 days)a | IESBaseline, Posttreatment, follow-up time varied | Government |
| Yeh et al., 201199Brazil | Randomized:35G1: 17G2: 18Analyzed: 31G1: 17G2: 14 | Outpatient special MH12 wks | CAPS Baseline & Posttreatment | Foundation/non-profit |

Table D-1. Characteristics of included randomized trials (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, YearCountry | Group Sample Sizes | SettingStudy Duration | Primary Outcome& Timing ofAssessment | FundingSource |
| Zlotnick et al., 2009100United States | Randomized: 49G1: 27G2: 22Analyzed: 44G1: 23G2: 21 | Prison6 to 8 wks | CAPSBaseline, Posttreatment, 3 mths, 6 mths | Government |
| Zohar et al., 2002101Israel | Randomized: UnclearG1: NRG2: NRAnalyzed: 42G1: 23G2: 19 | Military10 wks | CAPS-2Baseline & Posttreatment | Pharmaceutical company |

aNumber of treatment sessions reported when duration of treatment not specified

Abbreviations: CAPS = Clinician-Administered PTSD Scale; CAPS-1 = Clinician-Administered PTSD Scale, Version 1; CAPS-2 = Clinician-Administered PTSD Scale, Version 2; CAPS-SX = Clinician-Administered PTSD Scale; DTS = Davidson Trauma Scale; Dx = diagnosis; G = group; HTQ = Harvard Trauma Questionnaire; IES = Impact of Event Scale; MH = mental health; mths = months; NR = not reported; PC = patient center; PCL-C = Posttraumatic stress disorder checklist-civilian version; PCL-M = Posttraumatic stress disorder checklist-military version; PDS = Posttraumatic Stress Diagnostic Scale; PSQI = Pittsburgh Sleep Quality Index; PSS =PTSD Symptom Scale; PSS-I = PTSD Symptom Scale Interview; PSS-SR = PTSD Symptom Scale Self-report Version; Psych = psychiatric; PTSD = Posttraumatic Stress Disorder; SCL-90 = 90 item symptoms checklist; SI-PTSD = Structured Interview for PTSD; SPRINT = Short PTSD Rating Interview; Sx = serious; TOP-8 = Treatment-outcome posttraumatic; stress disorder scale (8 item); VA = Veterans Administration; wks = weeks; Yr = year.